Fig. 3From: A real-world economic analysis of biologic therapies for psoriatic arthritis in Italy: results of the CHRONOS observational longitudinal studyCost per good/moderate EULAR DAS28 sustained responder ratio at 12 months (overall cohort). DAS28: Disease Activity Score 28 jointsBack to article page